11 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 16 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 11, Recruiting 3, Active not recruiting 1, Terminated 1 |
| Phase 1 | 6 | Completed 2, Recruiting 2, Active not recruiting 1, Terminated 1 |
Follow Folotyn: new trials by email Literature Review of Folotyn trials Research Report on Folotyn
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Azacytidine, Romidepsin, Belinostat - PTCL | Phase 2 | Recruiting | University of Virginia | 50 | 2021-02-19 | 2026-01-21 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-25 | 2026-10-29 |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Durvalumab, Pralatrexate, Romidepsin - Lymphoma, T-Cell | Phase 1 / Phase 2 | Recruiting | University of Virginia | 148 | 2018-05-30 | 2022-03-31 |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Pralatrexate, Romidepsin - Lymphoid Malignancies, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Jennifer Amengual | 57 | 2013-09-09 | 2026-09-16 |
| KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) KW-0761, Pralatrexate, gemcitabine plus oxaliplatin - Adult T-cell Leukemia-Lymphoma | Phase 2 | Completed | Kyowa Kirin, Inc. | 71 | 2012-06-01 | 2024-04-25 |
| Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma prednisone, cyclophosphamide, etoposide - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | University of Nebraska | 34 | 2011-07-06 | 2023-09-22 |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate - Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 35 | 2010-09-01 | 2017-12-13 |
| Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy pralatrexate, docetaxel, fludeoxyglucose F 18 - Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 6 | 2010-07-01 | 2016-06-01 |
| Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer Pralatrexate Injection, Vitamin B12, Folic Acid - Breast Cancer, Breast Tumors | Phase 2 | Completed | Acrotech Biopharma Inc. | 22 | 2010-03-01 | 2020-01-07 |
| Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Pralatrexate, Vitamin B12, Folic Acid - Lymphoma, B-Cell | Phase 2 | Completed | Spectrum Pharmaceuticals, Inc | 29 | 2009-09-01 | 2021-11-05 |
| Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder Pralatrexate Injection, Vitamin B12, Folic Acid - Carcinoma, Transitional Cell, Bladder Cancer | Phase 2 | Completed | Acrotech Biopharma Inc. | 30 | 2008-07-01 | 2019-12-17 |
| Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment Pralatrexate, Erlotinib, Vitamin B12 - Non-small Cell Lung Cancer | Phase 2 | Completed | Spectrum Pharmaceuticals, Inc | 201 | 2008-01-01 | 2021-03-05 |
| Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12 - Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | Acrotech Biopharma Inc. | 119 | 2007-05-01 | 2020-01-07 |
| Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Pralatrexate Injection - Peripheral T-cell Lymphoma | Phase 2 | Completed | Acrotech Biopharma Inc. | 115 | 2006-08-01 | 2019-12-19 |
| 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma pralatrexate - Lymphoma | Phase 1 / Phase 2 | Completed | Spectrum Pharmaceuticals, Inc | 72 | 2002-08-01 | 2021-08-25 |
Lymphoma, T-Cell (5) · Lymphoma (4) · Lymphoma, Large-Cell, Anaplastic (4) · Lymphoma, T-Cell, Peripheral (4) · Hodgkin Disease (3) · Immunoblastic Lymphadenopathy (3) · Lymphoma, Follicular (3) · Lymphoma, Non-Hodgkin (3) · Recurrence (3) · Adenocarcinoma Of Esophagus (2) · Burkitt Lymphoma (2) · Esophageal Squamous Cell Carcinoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2)
Acrotech Biopharma Inc. (4) · Spectrum Pharmaceuticals, Inc (3) · University of Virginia (2) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Jennifer Amengual (1) · Kyowa Kirin, Inc. (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · University of Nebraska (1)
United States (16) · France (4) · Belgium (3) · Argentina (2) · Brazil (2) · Czechia (2) · Hungary (2) · United Kingdom (2) · Canada (1) · Croatia (1) · India (1) · Italy (1) · Peru (1) · Spain (1)
Garry Weems, PharmD (2) · Alex F Herrera (1) · Craig Portell, MD (1) · Enrica Marchi, M.D., PhD (1) · Garry Weems, Pharm.D. (1) · Jennifer Amengual, MD (1) · Julie M Vose (1) · Lorenzo Iovino, MD, PhD (1) · Michael Kurman, MD (1) · Michael Saunders, MD (1) · Nikhil Khushalani (1) · Owen A. O'Connor, MD, PhD (1) · Owen O'Connor, MD, PhD (1) · Tony Saab, MD (1)
PMID 19652067, PMID 29141948, PMID 38517235, PMID 40932107
2008 (1), P30CA016056 (1), P30CA036727 (1)